注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Athira Pharma Inc是一家临床阶段的生物制药公司。该公司专注于开发小分子以恢复神经元健康和阻止神经退行性变。该公司的主要候选药物fosgonimeton (ATH-1017)是一种皮下给药、可穿透血脑屏障(BBB)的小分子HGF/MET正调节剂。该药物主要目标适应症是阿尔茨海默病。ATH-1017是一种皮下给药、穿透BBB的小分子肝细胞生长因子/间充质-上皮转化因子 (HGF/MET) 激活剂,用于治疗神经退行性疾病,最初的重点是阿尔茨海默病 (AD)。该公司还拥有非AD适应症的临床前候选药物,包括正在开发用于解决外周适应症的ATH-1018,以及正在开发用于解决神经精神适应症的ATH-1019/ATH-1020化合物。ATH技术旨在促进各种临床应用的HGF/MET活性。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Kelly A. Romano | 60 | 2020 | Independent Chairwoman of the Board |
Mark J. Litton | 54 | 2019 | President, CEO & Director |
John M. Fluke | 79 | 2014 | Independent Director |
Joseph Eric Edelman | 66 | 2020 | Independent Director |
Marwan Noel Sabbagh | 56 | 2022 | Member of Scientific Advisory Board |
Grant E. Pickering | 54 | 2022 | Independent Director |
James A. Johnson | 65 | 2020 | Independent Director |
Barbara A. Kosacz | 64 | 2021 | Independent Director |
Anton P. Porsteinsson | - | 2022 | Member of Scientific Advisory Board |
Michael A. Panzara | 56 | 2022 | Independent Director |
John Olichney | - | 2022 | Member of Scientific Advisory Board |
Lon S. Schneider | - | 2022 | Member of Scientific Advisory Board |
Paul Winner | - | 2022 | Member of Scientific Advisory Board |
Pierre N. Tariot | - | 2022 | Member of Scientific Advisory Board |
Hans Moebius | 67 | 2019 | Chairman of Scientific Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核